Enem Nostrum Remedies Private Limited - Company Profile

It is a pharma private limited company based in Mumbai, Maharashtra, India, established in 2001.
2001 Mumbai, Maharashtra, India Active
Last Updated:
Access Report
About Enem Nostrum Remedies Private Limited

Enem Nostrum Remedies Private Limited, a active private limited company, was established on 01 January 2001 in Mumbai, Maharashtra, India. Engaging in pharma contract r&d within the professional, scientific and technical sector, it holds CIN: U24229MH2001PTC130260. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹4.35 Cr and a paid-up capital of ₹2.35 Cr.

It upholds a compliant status. Employing 143 professional, Its leadership includes Anilkumar Shridhar Mulye (Director), Shraddha Vinayak Dhamankar (Director). Past directors included Jayant Hari Ranade, Prashant Raghunandan Rele, Nirmal Vasant Mulye. It holds ₹40.14 Cr open charges and ₹104.69 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at 201-204, Gayatri Commercial Complex, Behind Mittal Ind.Estate, Kurla-Andheri Road, Andheri, (E),, Mumbai, Maharashtra, 400059.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24229MH2001PTC130260

  • Registration Number

    130260

  • Incorporation Date

    01 January 2001

  • Authorized Capital

    ₹4.35 Cr

  • Paid-Up Capital

    ₹2.35 Cr

  • ROC Code

    Roc Mumbai

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 4.35 Cr
  • Paid Up Capital ₹ 2.35 Cr
  • Company Age 25 Year, 1 Month
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 40.14 Cr
  • Satisfied Charges ₹ 104.69 Cr
  • Revenue Growth **** 2.28%
  • Profit Growth **** -38.48%
  • Ebitda **** 30.81%
  • Net Worth 1.79%
  • Total Assets **** 14.27%
Company report

Enem Nostrum Remedies Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Enem Nostrum Remedies Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Enem Nostrum Remedies Private Limited?
Current Directors
Name Designation Appointment Date Status
Anilkumar Shridhar Mulye Director 16 Sep 2024 Current
Shraddha Vinayak Dhamankar Director 01 Jan 2001 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 15 Sep 2024 Past
Pramod Abcsdd Director 05 Jan 2010 Past
Pramod Abcsdd Director 21 Apr 2025 Past
Pramod Abcsdd Director 07 Jul 2013 Past
Pramod Abcsdd Additional Director 30 Dec 2024 Past
Pramod Abcsdd Director 30 Jul 2019 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Enem Nostrum Remedies.

Enem Nostrum Remedies Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.28% increase. The company also saw a substantial fall in profitability, with a 38.48% decrease in profit. The company's net worth moved up by a moderate rise of 1.79%.

Enem Nostrum Remedies revenue growth over time
Enem Nostrum Remedies profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 2.28%
*******
*******
*******
*******
Revenue from Operations
*******
 4.38%
*******
*******
*******
*******
Total Assets
*******
 14.27%
*******
*******
*******
*******
Profit or Loss
*******
 -38.48%
*******
*******
*******
*******
Net Worth
*******
 1.79%
*******
*******
*******
*******
EBITDA
*******
 30.81%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Enem Nostrum Remedies?

In 2023, Enem Nostrum Remedies had a promoter holding of 99.99%. The company had 6 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹401,439,600.00

Satisfied Charges

₹1,046,857,680.00

Charges Breakdown by Lending Institutions
  • Bank Of India : 37.11 Cr
  • Biotechnology Industry Research Assistance Council : 2.56 Cr
  • Others : 0.48 Cr
Latest Charge Details
Date Lender Amount Status
05 Dec 2022 Bank Of India ₹37.11 Cr Open
04 Mar 2022 Others ₹4.77 M Open
14 Feb 2014 Biotechnology Industry Research Assistance Council ₹2.56 Cr Open
11 Mar 2022 Others ₹4.77 M Satisfied
16 Dec 2021 Hdfc Bank Limited ₹21.89 Cr Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Enem Nostrum Remedies?

Enem Nostrum Remedies has a workforce of 143 employees as of Mar 26, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Enem Nostrum Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Enem Nostrum Remedies's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Enem Nostrum Remedies
Recent Activity within the Organization
  • Annual General Meeting

    Enem Nostrum Remedies Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was recorded as a recent event.

  • Charges

    A charge registered on 11 Mar 2022 via Charge ID 100562502 with Others was fully satisfied on 06 May 2025. was recorded as a recent event.

  • Balance Sheet

    Enem Nostrum Remedies Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was recorded as a recent event.

  • Director Appointment

    Progress on Anilkumar Shridhar Mulye was appointed as a Director was appointed as a Director on 16 Sep 2024 & has been associated with this company since 1 year 5 months . was documented.

  • Charges

    A charge with Bank Of India of Rs. 37.11 Cr registered on 05 Dec 2022 with Charge ID 100666599 was modified on 11 Jul 2023. was recorded as a recent event.

  • Charges

    A charge registered on 16 Dec 2021 via Charge ID 100514737 with Hdfc Bank Limited was fully satisfied on 21 Dec 2022. was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Enem Nostrum Remedies Private Limited?

The CIN of Enem Nostrum Remedies Private Limited is U24229MH2001PTC130260.

Where is Enem Nostrum Remedies Private Limited headquartered?

Enem Nostrum Remedies Private Limited is headquartered at 201-204, Gayatri Commercial Complex, Behind Mittal Ind.Estate, Kurla-Andheri Road, Andheri, (E),, Mumbai, Maharashtra, 400059.

When was Enem Nostrum Remedies Private Limited incorporated?

Enem Nostrum Remedies Private Limited was incorporated on 01 January 2001.

Who are the current directors of Enem Nostrum Remedies Private Limited?

The current directors of Enem Nostrum Remedies Private Limited are

What is the primary industry of Enem Nostrum Remedies Private Limited?

The primary industry of Enem Nostrum Remedies Private Limited is Professional, Scientific And Technical.

Is Enem Nostrum Remedies Private Limited a listed company?

Enem Nostrum Remedies Private Limited is unlisted.

What is the capital structure of Enem Nostrum Remedies Private Limited?

The authorized capital of Enem Nostrum Remedies Private Limited is ₹4.35 Cr, and the paid-up capital is ₹2.35 Cr.

What is the compliance status of Enem Nostrum Remedies Private Limited?

The compliance status of Enem Nostrum Remedies Private Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available